Drug intelligence / Profile preview

BMS-135

Development stage: Preclinical
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

BMS-135 is a novel, potent small molecule inhibitor of Casein Kinase II (CK2) developed by Bristol Myers Squibb. CK2 is a serine/threonine kinase that is frequently overexpressed in various malignancies, including acute myeloid leukemia (AML), where it plays a critical role in promoting cell survival, proliferation, and resistance to therapy. Preclinical studies have demonstrated that BMS-135 induces G0-G1 cell cycle arrest and apoptosis in AML cell lines and patient-derived xenograft models. Furthermore, BMS-135 has shown synergistic cytotoxic activity when combined with standard chemotherapy agents such as daunorubicin and cytarabine, suggesting its potential as a combination therapy for drug-resistant AML.

Targets

CK2 (Casein kinase II subunit alpha)CSNK2A2 (Casein kinase II subunit alpha prime)

Beyond the preview

Go deeper on BMS-135.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-135.

Explore the full profile